Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Synuclein-One Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04700722
Recruitment Status : Recruiting
First Posted : January 8, 2021
Last Update Posted : February 18, 2021
Sponsor:
Information provided by (Responsible Party):
CND Life Sciences

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Condition or disease Intervention/treatment
Parkinson Disease Multiple System Atrophy Dementia With Lewy Bodies Pure Autonomic Failure Diagnostic Test: Skin Biopsy

Detailed Description:
Phosphorylated α-synuclein pathology in the diagnosis of synucleinopathies through qualitative and quantitative measurements of cutaneous phosphorylated α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. An effective tissue biomarker will provide an accurate diagnosis of α-synuclein in clinical practice, will differentiate between synucleinopathies, enable assessment of target engagement in the development of disease modifying and neuroprotective therapies and accelerate the development of neuroprotective and disease modifying therapies.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Actual Study Start Date : January 4, 2021
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Parkinson's disease
Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
 Diagnostic Test: Skin Biopsy
Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
Multiple System Atrophy
Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
 Diagnostic Test: Skin Biopsy
Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
Dementia with Lewy bodies
Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
 Diagnostic Test: Skin Biopsy
Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
Pure Autonomic Failure
Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
 Diagnostic Test: Skin Biopsy
Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
Healthy Controls
No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
 Diagnostic Test: Skin Biopsy
Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Primary Outcome 1 [ Time Frame: 2 years ]
    To define test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein.

  2. Primary Outcome 2 [ Time Frame: 2 years ]
    To define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein.

  3. Primary Outcome 3 [ Time Frame: 2 years ]
    To differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.


Biospecimen Retention:   Samples Without DNA
Skin Biopsy

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Eligible men and women, age 40-99 years, will undergo a screening evaluation that includes a thorough medical history, physical and neurologic exam, orthostatic vitals, questionnaires and skin biopsy completed in one visit.
Criteria

Inclusion Criteria:

  • Male and female between 40-99 years of age
  • Prior clinical diagnosis of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure
  • Health Subjects, no history of clinical or symptoms suggestive with synucleinopathy

Exclusion Criteria:

  • Clinical evidence of severe vascular disease (history of ulceration, poor wound healing, vascular claudication)
  • Clinically active coronary artery or cerebrovascular disease
  • Current smoker or alcoholism
  • History of allergic reaction to local anesthesia for skin biopsies
  • Use of blood thinners (aspirin or Plavix alone is allowed)
  • Significantly impaired wound healing or history of scarring or keloid formation
  • Healthy individuals or individuals with synucleinopathy is disease may be explained by other causes: recent history of encephalitis, Cortical dementia of Alzheimer's type, Whipple's disease, toxin exposure, repeated head injury and stepwise disease progression suggestive of vascular etiology
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04700722


Contacts
Layout table for location contacts
Contact: Jade Stohl 480-569-2900 ext 105 jstohl@cndlifesciences.com
Contact: Todd Levine, MD 480-569-2900 levine@cndlifesciences.com

Locations
Layout table for location information
United States, Arizona
CND Life Sciences Recruiting
Phoenix, Arizona, United States, 85018
Contact: Jade Stohl    480-569-2900 ext 105    jstohl@cndlifesciences.com   
Principal Investigator: Todd Levine         
Movement Disorders Center of Arizona Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Susan Ortega    480-526-5441    susan@movementdisorders.us   
Contact: Danica Evidente    480-526-5441    danica@movementdisorders.us   
Principal Investigator: Virgilio Evidente         
United States, California
The Neuro Center Recruiting
Carlsbad, California, United States, 92011
Contact: Estela Soto    760-732-0557 ext 2123    estela.soto@neurocenter.com   
Contact: Guadalupe Sanchez    760-732-0557 ext 2147    lupe.sanchez@neurocenter.com   
Principal Investigator: Gregory Sahagian         
United States, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton Recruiting
Boca Raton, Florida, United States, 33486
Contact: Randi Provenzano       rprovenzano@parkinsonscenter.org   
Contact: Jocelyne Fimiano       jfimiano@parkinsonscenter.org   
Principal Investigator: Stuart Isaacson         
United States, Illinois
NorthShore University Health System Recruiting
Evanston, Illinois, United States, 60201
Contact: Lisette Garduno    847-503-4334    lgarduno@northshore.org   
Contact: Roberta Frigerio    8475034334    rfrigerio@northshore.org   
Principal Investigator: Alex Barboi         
Sponsors and Collaborators
CND Life Sciences
Investigators
Layout table for investigator information
Principal Investigator: Todd Levine, MD CND Life Sciences: www.cndlifesciences.com
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: CND Life Sciences
ClinicalTrials.gov Identifier: NCT04700722    
Other Study ID Numbers: CND-100
First Posted: January 8, 2021    Key Record Dates
Last Update Posted: February 18, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will be shared with researchers that are involved in the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CND Life Sciences:
Neurodegenerative Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Multiple System Atrophy
Shy-Drager Syndrome
Pure Autonomic Failure
Lewy Body Disease
Atrophy
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Movement Disorders
Neurodegenerative Diseases
Dementia
Neurocognitive Disorders
Mental Disorders
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Hypotension
Vascular Diseases
Cardiovascular Diseases